Statins should be considered for primary prevention in people living with HIV who are at low-to-moderate risk of cardiovascular disease, according to final data from the REPRIEVE trial that show pitavastatin therapy is associated with a significantly lower risk of cardiovascular events than placebo.

"There was a significant 35% lower ...